Karuna Therapeutics Future Growth
Future criteria checks 5/6
Karuna Therapeutics is forecast to grow earnings and revenue by 60% and 51.9% per annum respectively. EPS is expected to grow by 60.2% per annum. Return on equity is forecast to be -49.7% in 3 years.
Key information
60.0%
Earnings growth rate
60.2%
EPS growth rate
Biotechs earnings growth | 0% |
Revenue growth rate | 51.9% |
Future return on equity | -49.7% |
Analyst coverage | Good |
Last updated | 22 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 704 | 90 | 286 | 344 | 11 |
12/31/2025 | 258 | -281 | -195 | -233 | 16 |
12/31/2024 | 53 | -433 | -432 | -441 | 20 |
12/31/2023 | 1 | -434 | -389 | -386 | N/A |
9/30/2023 | 6 | -396 | -356 | -354 | N/A |
6/30/2023 | 6 | -354 | -305 | -303 | N/A |
3/31/2023 | 11 | -316 | -280 | -279 | N/A |
12/31/2022 | 11 | -276 | -229 | -228 | N/A |
9/30/2022 | 42 | -228 | -158 | -156 | N/A |
6/30/2022 | 42 | -202 | -143 | -140 | N/A |
3/31/2022 | 37 | -172 | -133 | -130 | N/A |
12/31/2021 | 37 | -144 | -104 | -101 | N/A |
9/30/2021 | N/A | -140 | -119 | -117 | N/A |
6/30/2021 | N/A | -108 | -97 | -96 | N/A |
3/31/2021 | N/A | -90 | -83 | -83 | N/A |
12/31/2020 | N/A | -69 | -70 | -70 | N/A |
9/30/2020 | N/A | -52 | -54 | -54 | N/A |
6/30/2020 | N/A | -43 | -40 | -39 | N/A |
3/31/2020 | N/A | -41 | -33 | -33 | N/A |
12/31/2019 | N/A | -44 | -31 | -31 | N/A |
9/30/2019 | N/A | -45 | -31 | -31 | N/A |
6/30/2019 | N/A | -42 | -25 | -25 | N/A |
3/31/2019 | N/A | -27 | -21 | -21 | N/A |
12/31/2018 | N/A | -18 | -16 | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KRTX * is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.7%).
Earnings vs Market: KRTX * is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: KRTX * is expected to become profitable in the next 3 years.
Revenue vs Market: KRTX *'s revenue (51.9% per year) is forecast to grow faster than the MX market (6.6% per year).
High Growth Revenue: KRTX *'s revenue (51.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KRTX * is forecast to be unprofitable in 3 years.